The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Lung Cancer Diagnostics Market Research Report 2024
Synopsis
Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
The global Lung Cancer Diagnostics market was valued at US$ 1883.5 million in 2023 and is anticipated to reach US$ 2783 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Diagnostics.
Report Scope
The Lung Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lung Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche Diagnostics
BioMérieux
Qiagen
Advpharma
AIT Austrian Institute of Technology
Courtagen Life Sciences
DiagnoCure
BioMark Diagnostics
Mayo Clinic
HalioDx SAS
Segment by Type
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Biomarkers
Other
Segment by Application
Industrial
Healthcare
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
The global Lung Cancer Diagnostics market was valued at US$ 1883.5 million in 2023 and is anticipated to reach US$ 2783 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Diagnostics.
Report Scope
The Lung Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lung Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche Diagnostics
BioMérieux
Qiagen
Advpharma
AIT Austrian Institute of Technology
Courtagen Life Sciences
DiagnoCure
BioMark Diagnostics
Mayo Clinic
HalioDx SAS
Segment by Type
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Biomarkers
Other
Segment by Application
Industrial
Healthcare
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immunoassays
1.2.3 Flow Cytometry
1.2.4 Rapid Tests
1.2.5 Molecular Assays
1.2.6 Tissue Arrays
1.2.7 Circulating Tumor Cells
1.2.8 Pharmacodiagnostics
1.2.9 Biomarkers
1.2.10 Other
1.3 Market by Application
1.3.1 Global Lung Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Industrial
1.3.3 Healthcare
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Diagnostics Market Perspective (2019-2030)
2.2 Lung Cancer Diagnostics Growth Trends by Region
2.2.1 Global Lung Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Lung Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Lung Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Lung Cancer Diagnostics Market Dynamics
2.3.1 Lung Cancer Diagnostics Industry Trends
2.3.2 Lung Cancer Diagnostics Market Drivers
2.3.3 Lung Cancer Diagnostics Market Challenges
2.3.4 Lung Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Diagnostics Players by Revenue
3.1.1 Global Top Lung Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Lung Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Lung Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lung Cancer Diagnostics Revenue
3.4 Global Lung Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Lung Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnostics Revenue in 2023
3.5 Lung Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Lung Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Lung Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Diagnostics Breakdown Data by Type
4.1 Global Lung Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Lung Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Lung Cancer Diagnostics Breakdown Data by Application
5.1 Global Lung Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Lung Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Lung Cancer Diagnostics Market Size (2019-2030)
6.2 North America Lung Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Lung Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Lung Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lung Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Lung Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Lung Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Lung Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Lung Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Lung Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Lung Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lung Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Lung Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Lung Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Lung Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Lung Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Lung Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Lung Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche Diagnostics
11.1.1 Roche Diagnostics Company Detail
11.1.2 Roche Diagnostics Business Overview
11.1.3 Roche Diagnostics Lung Cancer Diagnostics Introduction
11.1.4 Roche Diagnostics Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.1.5 Roche Diagnostics Recent Development
11.2 BioMérieux
11.2.1 BioMérieux Company Detail
11.2.2 BioMérieux Business Overview
11.2.3 BioMérieux Lung Cancer Diagnostics Introduction
11.2.4 BioMérieux Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.2.5 BioMérieux Recent Development
11.3 Qiagen
11.3.1 Qiagen Company Detail
11.3.2 Qiagen Business Overview
11.3.3 Qiagen Lung Cancer Diagnostics Introduction
11.3.4 Qiagen Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.3.5 Qiagen Recent Development
11.4 Advpharma
11.4.1 Advpharma Company Detail
11.4.2 Advpharma Business Overview
11.4.3 Advpharma Lung Cancer Diagnostics Introduction
11.4.4 Advpharma Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.4.5 Advpharma Recent Development
11.5 AIT Austrian Institute of Technology
11.5.1 AIT Austrian Institute of Technology Company Detail
11.5.2 AIT Austrian Institute of Technology Business Overview
11.5.3 AIT Austrian Institute of Technology Lung Cancer Diagnostics Introduction
11.5.4 AIT Austrian Institute of Technology Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.5.5 AIT Austrian Institute of Technology Recent Development
11.6 Courtagen Life Sciences
11.6.1 Courtagen Life Sciences Company Detail
11.6.2 Courtagen Life Sciences Business Overview
11.6.3 Courtagen Life Sciences Lung Cancer Diagnostics Introduction
11.6.4 Courtagen Life Sciences Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.6.5 Courtagen Life Sciences Recent Development
11.7 DiagnoCure
11.7.1 DiagnoCure Company Detail
11.7.2 DiagnoCure Business Overview
11.7.3 DiagnoCure Lung Cancer Diagnostics Introduction
11.7.4 DiagnoCure Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.7.5 DiagnoCure Recent Development
11.8 BioMark Diagnostics
11.8.1 BioMark Diagnostics Company Detail
11.8.2 BioMark Diagnostics Business Overview
11.8.3 BioMark Diagnostics Lung Cancer Diagnostics Introduction
11.8.4 BioMark Diagnostics Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.8.5 BioMark Diagnostics Recent Development
11.9 Mayo Clinic
11.9.1 Mayo Clinic Company Detail
11.9.2 Mayo Clinic Business Overview
11.9.3 Mayo Clinic Lung Cancer Diagnostics Introduction
11.9.4 Mayo Clinic Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.9.5 Mayo Clinic Recent Development
11.10 HalioDx SAS
11.10.1 HalioDx SAS Company Detail
11.10.2 HalioDx SAS Business Overview
11.10.3 HalioDx SAS Lung Cancer Diagnostics Introduction
11.10.4 HalioDx SAS Revenue in Lung Cancer Diagnostics Business (2019-2024)
11.10.5 HalioDx SAS Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
